InvestorsHub Logo
Followers 119
Posts 19356
Boards Moderated 0
Alias Born 08/27/2005

Re: None

Saturday, 06/02/2018 7:46:16 PM

Saturday, June 02, 2018 7:46:16 PM

Post# of 404964
From 2000

Elite's Atul M. Mehta was recently issued a U.S. patent (No. 5,837,284) related to pulse dose methylphenidate products. The patent was exclusively licensed to Celgene Corp. (Warren, NJ), who then licensed the product to Novartis (see related article). Elite retains certain manufacturing rights for the patented product—which simulates two doses of the drug marketed as Ritalin—and also retained rights to its pulse dose technology as it relates to all non-methylphenidate drugs.


Hmmmmmmm interesting stuff alright! gggggg


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News